Knowledge graph · Trial
An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.
NOT YET RECRUITING
- Identifier
- CI-TRIAL-00086714
- Entity page
- /trial/NCT06855849 ↗
- Edges
- 0
- Neighbours
- none
- Drawn
- 0 of 0 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Data not yet available
No knowledge edge or registry link touches this trial on this environment. Edges appear once a source (CIViC, ChEMBL, openFDA, ClinicalTrials.gov, GDC) states one — CancerIndex does not infer them.
What CancerIndex knows
- Open An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.
- Lung Non-Small Cell Carcinoma
- Malignant Colorectal Neoplasm
- ABL1
- EGFR